John M. Mandrola, MD November 05, 2022 U.S. experts favor chlorthalidone over hydrochlorothiazide (HCTZ) in the first-line treatment of hypertension. Yet practicing doctors are approximately 20-fold more likely to choose HCTZ over chlorthalidone. During the opening late-breaking clinical trials session here at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, we learned that practicing doctors had it...